ArticleScientific reports2026
Integrative transcriptomic and machine learning framework reveals candidate genes and potential mechanisms of aflatoxin B1 exposure in breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aflatoxin B1 (AFB1), a known mycotoxin and environmental hazard, has been linked to breast cancer, yet the exact biological pathways remain poorly characterized. We performed a comprehensive multi-omics assessment to investigate how AFB1 may influence breast tumor biology. This encompassed transcriptomic analysis, co-expression network modeling (WGCNA), immune landscape profiling, transcription factor regulatory mapping, and spatial plus single-cell transcriptomics. Predictive biomarkers were determined through a machine learning pipeline. Twenty-two genes were identified at the intersection of AFB1-predicted targets and disease-associated expression modules. A refined panel of seven biomarkers (EGFR, MIF, MET, PPARG, MME, NQO2, NR3C2) was established through model optimization. A composite classifier using glmBoost and StepGLM achieved high discriminative accuracy (area under the curve = 0.996). SHAP interpretability indicated PPARG may act protectively, while MIF showed risk-promoting characteristics. Expression heterogeneity was observed across cell populations and spatial regions. Our integrated analytical framework offers new insights into the oncogenic potential of AFB1 in breast cancer. The identified gene set may serve as both mechanistic mediators and diagnostic markers, underscoring the value of multi-omics and machine learning approaches in environmental carcinogenesis research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.